GenoMed Scores 13th Victory Treating Neuroinvasive West Nile Virus in Humans
Posted on: Thursday, 1 September 2005, 12:00 CDT
ST. LOUIS, Sept. 1 /PRNewswire-FirstCall/ -- GenoMed Inc., ("the Company" or "GenoMed") (Pink Sheets: GMED) a St. Louis, Missouri-based Next Generation Disease Management company, announced today that it successfully treated its thirteenth patient with presumed West Nile virus encephalitis.
The patient is a previously healthy man from Aberdeen, South Dakota who developed fever and headache and was diagnosed by his physician as having West Nile virus on Monday of this week. South Dakota has about 50 times higher incidence of West Nile virus this summer than California.
The patient found GenoMed on the Internet, and within 2 hours his physician had started him on an angiotensin II receptor blocker, GenoMed's patent-pending approach to most viral diseases, including West Nile virus. The patient's headache intensified over the next 24 hours, requiring a visit to the Emergency Room, where he was offered a spinal tap, but not hospitalized. The patient went home and slept most of the following day. He awoke in the afternoon without a high fever or neck stiffness any more.
David Moskowitz MD, FACP, GenoMed's Chief Medical Officer and CEO, commented, "This patient demonstrated an extremely rapid resolution of his symptoms, several days faster than expected. Our treatment failed to prevent progression to meningitis, which we've seen before, but it did result in an extremely rapid recovery thereafter, within the next 24 hours. The patient could just as easily have progressed to full-blown coma, which was a concern the night he went to the ER. Normally it takes 3-6 days to recover from West Nile virus meningo-encephalitis. This patient's total recovery time was a bit under 48 hours, and under 24 hours from his worst symptoms of neck stiffness or meningitis."
During the past three summers, GenoMed has treated 16 patients, of whom this patient represents the 13th treatment success (81%). GenoMed has had a 50% treatment success rate in birds, and is eager to treat horses, also.
To enroll in GenoMed's free clinical trial, which uses already existing, safe medication present in every drug store and hospital, just go to http://www.genomed.com/ and click on the link for the West Nile virus trial.
About GenoMed
GenoMed has found what it believes to be the "master" disease gene, and has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of terminal emphysema; and begin to see success in treating autoimmune diseases, West Nile virus encephalitis, and cancer. GenoMed's broad-spectrum anti-viral approach was specifically mentioned in BioShield II, recently introduced in the US Senate (see Section 2151 of Senate bill S. 975). GenoMed has recently found several thousand genes for the top six solid cancers in Caucasians -- breast, colon, lung, ovarian, pancreatic, and prostate -- and is currently offering its Healthchip(r) for early diagnosis of cancer on a research basis.
Safe Harbor Statement
This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to,""should,""could,""may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward- looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
GenoMed Inc.
CONTACT: David Moskowitz MD, of GenoMed, Inc., +1-314-983-9933,dwmoskowitz@genomed.com
Web site: http://www.genomedics.com/
Source: PRNewswire-FirstCall
Related Articles
- Entergy Issues Forward Looking Financial Update and Announces $750 Million Share Repurchase Program Authorization
- CACI Awarded Task Order Valued at $40 Million to Support U.S. Army Forward Looking Infrared Systems
- Devon Energy Provides Forward-Looking Estimates of Production, Reserve Additions and Capital Expenditures
- River Hawk CEO Outlines Capital Structure and Forward-Looking Plan
- BIO Applauds House Passage of Forward-Looking Farm Bill
- BIO Commends House Agriculture Committee on Forward-Looking Farm Bill
- Cosmetic Surgery Patients Give Public First Glimpse of 'New Look' at Fall Fashion Show
- Bernanke Says Fed Policy Must Be Forward-looking
- Sendmail Partners With Commtouch to Combat Spam and Viruses at Zero-Hour
- Westinghouse Lauds Progress Energy for Proactive, Forward-Looking Approach to Nuclear Fleet Expansion
 |
 |
User Comments (0)
RSS Feeds